Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Equity (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Return on Equity for 15 consecutive years, with 0.11% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 77.0% to 0.11% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.11%, a 77.0% increase, with the full-year FY2024 number at 0.18%, up 216.0% from a year prior.
  • Return on Equity was 0.11% for Q3 2025 at Gyre Therapeutics, up from 0.07% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.22% in Q3 2022 to a low of 1.85% in Q1 2022.
  • A 5-year average of 0.56% and a median of 0.49% in 2023 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 207bps in 2023; the steepest drop was -179bps in 2023.
  • Gyre Therapeutics' Return on Equity stood at 1.46% in 2021, then surged by 105bps to 0.07% in 2022, then plummeted by -2655bps to 1.72% in 2023, then surged by 111bps to 0.19% in 2024, then plummeted by -39bps to 0.11% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Return on Equity are 0.11% (Q3 2025), 0.07% (Q2 2025), and 0.09% (Q1 2025).